TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8568424

Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude cervical manipulation twice/wk for 3 wk
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low-level laser in the upper cervical region and deep friction massage in the lower cervical/upper thoracic region, twice/wk for 3 wk
Number of subjects: 39
Study: 1814714

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Fuji II/G‐C Dental)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Ketac Fil/ESPE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sandwich restoration (Lining Cement/G‐C Dental)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sandwich restoration (Ketac Bond/ESPE)
Number of subjects: 19
Study: 7025171

Group type: EXPERIMENTAL
Intervention: Conventional toothbrush with modified handle
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Finger-stall attached to a normal toothbrush
Number of subjects: 21
Study: 31669890

Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (ld-IL2) combined with conventional therapy in 35 patients
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional therapy only in 26 patients
Number of subjects: 71

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overall findings in PM/DM
Number of subjects: 71
Study: 29603865

Group type: EXPERIMENTAL
Intervention: Whitening toothpaste (Sorriso Dentes Brancos, Colgate Luminous White, Close up White Now)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-whitening toothpaste (SDB)
Number of subjects: 30
Study: 26284983

Group type: EXPERIMENTAL
Intervention: Small ball size training group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bigger ball size training group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 22
Study: 24139833

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 72
Study: 22315364

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 6729
Study: 20558004

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethylstarch (HES)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Crystalloid (Hartmann's solution)
Number of subjects: 26
Study: 17401606

Group type: EXPERIMENTAL
Intervention: Long-acting medications for ADHD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cost-utility analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic evaluations
Number of subjects: 0
Study: 14762867

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) at a dose of 10mg/kg/h
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Aprotinin (AP) with a loading dose of 2 x 10(6) KIU followed by an infusion of 500,000 KIU/h
Number of subjects: 127
Study: 11297752

Group type: EXPERIMENTAL
Intervention: High-fat diet rich in monounsaturated fatty acids (MUFA) and marine n-3 polyunsaturated fatty acids (PUFA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-fat diet rich in complex carbohydrates and dietary fiber
Number of subjects: 25
Study: 9395119

Group type: EXPERIMENTAL
Intervention: 1.5% SLS/0.15% triclosan/0.3% zinc citrate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1.5% SLS/0.15% triclosan
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1.5% SLS/0.5% zinc citrate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1.5% SLS/PG (1:8)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1.5% SLS
Number of subjects: 15
Study: 7514366

Group type: EXPERIMENTAL
Intervention: 2 mg of risperidone
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: 6 mg of risperidone
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: 10 mg of risperidone
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: 16 mg of risperidone
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: 20 mg of haloperidol
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 3286831

Group type: EXPERIMENTAL
Intervention: Simultaneous MTX-FU therapy (MTX 200 mg/m2 IV, FU 600 mg/m2 IV)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Sequential MTX-FU therapy (MTX 200 mg/m2 IV, FU 600 mg/m2 IV)
Number of subjects: 113
Study: 28340306

Group type: COMPARATOR
Intervention: Group I (no PEEP)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Group II (PEEP 5 cmH2O)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Group III (PEEP 8 cmH2O)
Number of subjects: 105
Study: 27716600

Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 69

Group type: COMPARATOR
Intervention: Perforator
Number of subjects: 69
Study: 25522389

Group type: EXPERIMENTAL
Intervention: Ultrabrief pulse RUL ECT (8 times seizure threshold)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Brief pulse RUL ECT (5 times seizure threshold)
Number of subjects: 102
Study: 22516146

Group type: COMPARATOR
Intervention: General Hospital (GH) control group
Number of subjects: 272

Group type: COMPARATOR
Intervention: General Practice (GP) control group
Number of subjects: 272
Study: 20180789

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg before breakfast
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg before lunch
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg before dinner
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg before evening snack
Number of subjects: 48
Study: 17629999

Group type: EXPERIMENTAL
Intervention: Protak (Group A)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: EndoANCHOR (Group B)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: EMS (Group C)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Tissucol (Group D)
Number of subjects: 600
Study: 16183652

Group type: EXPERIMENTAL
Intervention: Home safety programme delivered by an occupational therapist (n = 100)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Exercise programme prescribed at home by a physiotherapist plus vitamin D supplementation (n = 97)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Both interventions (n = 98)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Social visits (n = 96)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Home safety programme
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Exercise programme with vitamin D supplementation
Number of subjects: 391
Study: 11840054

Group type: EXPERIMENTAL
Intervention: Telephonic nursing case management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10341274

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 1265

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1265
Study: 8942890

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost applied topically once daily for 12 months
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 198
Study: 1827095

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg 12‐hourly for 7‐14 days
Number of subjects: 125

Group type: COMPARATOR
Intervention: Ampicillin 250 mg 6‐hourly for 7‐14 days
Number of subjects: 125
Study: 7083750

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neostigmine and Propranolol (combined)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (age‐matched normal subjects)
Number of subjects: 18
Study: 31547205

Group type: EXPERIMENTAL
Intervention: Average daily physical activity level (PAL)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Day-to-day variations in PAL (SD of PAL)
Number of subjects: 14
Study: 28660441

Group type: EXPERIMENTAL
Intervention: Paclitaxel-resveratrol drug matrix-coated balloon catheter (DCB)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 153
Study: 26455138

Group type: EXPERIMENTAL
Intervention: 3-D external fixators
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intramedullary nails
Number of subjects: 45

Group type: COMPARATOR
Intervention: Plate
Number of subjects: 45
Study: 24560554

Group type: EXPERIMENTAL
Intervention: 3-plane clear corneal incision created using a 150 kHz femtosecond laser
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-plane angled clear corneal incision created using disposable knives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of both methods
Number of subjects: 0
Study: 23051145

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (10 minutes of forearm ischemia and reperfusion)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No ischemic preconditioning
Number of subjects: 36
Study: 19168907

Group type: EXPERIMENTAL
Intervention: Partial coherence interferometry (PCI)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Applanation ultrasound biometry (AUS)
Number of subjects: 205
Study: 17419885

Group type: EXPERIMENTAL
Intervention: Feedback-controlled training during single leg squat (SLS) exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Single leg squat (SLS) exercise without feedback
Number of subjects: 15
Study: 15040645

Group type: EXPERIMENTAL
Intervention: Intervention by physician and pharmacist
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Intervention by physician only
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Intervention by pharmacist only
Number of subjects: 712

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Generic health-related quality of life
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Symptom profile and side effects from antihypertensive drugs
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Number of emergency department visits and hospitalizations
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Blood pressure measurements
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Patient satisfaction with physicians and pharmacists
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Drug therapy compliance
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Health care charges
Number of subjects: 712
Study: 11782828

Group type: EXPERIMENTAL
Intervention: Mothers with SCI
Number of subjects: 310

Group type: COMPARATOR
Intervention: Able-bodied mothers
Number of subjects: 310
Study: 9437974

Group type: EXPERIMENTAL
Intervention: Clinical neurosensory test (NST) for LN injuries
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Clinical neurosensory test (NST) for IAN injuries
Number of subjects: 130
Study: 8042129

Group type: EXPERIMENTAL
Intervention: Single-dose oral therapy for gonorrhea (cefixime, ciprofloxacin, ofloxacin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose oral therapy for chlamydia (azithromycin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose oral therapy for chancroid (azithromycin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient therapy for pelvic inflammatory disease (ofloxacin and either clindamycin or metronidazole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-applied therapy for genital warts (podofilox)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syphilis therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prevention of sequelae and transmission
Number of subjects: 0
Study: 3542851

Group type: EXPERIMENTAL
Intervention: Zidometacin (400 mg p.o.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zidometacin (600 mg rectal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zidometacin (capsules)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zidometacin (suppositories)
Number of subjects: 20
Study: 30417857

Group type: EXPERIMENTAL
Intervention: HFS patients
Number of subjects: 86

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 86
Study: 26778459

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI) and diffusion tensor imaging (DTI)
Number of subjects: 64
Study: 24865394

Group type: EXPERIMENTAL
Intervention: Community-based recreational football, details on dosage and duration not available
Number of subjects: 0
Study: 22609108

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m(2) and nedaplatin 80 mg/m(2) intravenously on day 1 every 28 days
Number of subjects: 50
Study: 20595308

Group type: EXPERIMENTAL
Intervention: Customized electronic alert requiring affirmative response
Number of subjects: 1963

Group type: COMPARATOR
Intervention: Commercially available passive alert
Number of subjects: 1963
Study: 18540731

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Program (CRP)
Number of subjects: 161
Study: 18716003

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15957718

Group type: EXPERIMENTAL
Intervention: Low-flow sevoflurane (1 litre/min, n=9)
Number of subjects: 25

Group type: COMPARATOR
Intervention: High-flow sevoflurane (5 litre/min, n=7)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-flow isoflurane (1 litre/min, n=9)
Number of subjects: 25
Study: 11179983

Group type: EXPERIMENTAL
Intervention: Low M (omeprazole 20 mg twice daily, amoxycillin 1,000 mg twice daily, metronidazole 400 mg twice daily)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Medium M (omeprazole 40 mg once daily, amoxycillin 500 mg three times daily, metronidazole 400 mg three times daily)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: High M (omeprazole 20 mg twice daily, amoxycillin 1,000 mg twice daily, metronidazole 800 mg twice daily)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Metronidazole susceptible strains
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Metronidazole resistant strains
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Low M (susceptible/resistant)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Medium M (susceptible/resistant)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: High M (susceptible/resistant)
Number of subjects: 394
Study: 9268976

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1000
Study: 8471402

Group type: EXPERIMENTAL
Intervention: Quinidine dihydrochloride 10 mg kg‐1 body weight by intravenous infusion over 1 h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Quinine 10 mg kg‐1 body weight by intravenous infusion over 1 h
Number of subjects: 8
Study: 2869795

Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Loprazolam (1 mg)
Number of subjects: 8
Study: 30944068

Group type: EXPERIMENTAL
Intervention: Drug Coated Balloon (DCB; coated with paclitaxel)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 60
Study: 30203771

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0
Study: 26991622

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (Group E)
Number of subjects: 90
Study: 24805894

Group type: EXPERIMENTAL
Intervention: Cognitive Symptom Management and Rehabilitation Therapy (CogSMART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced supported employment (control)
Number of subjects: 0
Study: 22721596

Group type: EXPERIMENTAL
Intervention: Atomoxetine 1.2 mg/kg/day
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 19580719

Group type: EXPERIMENTAL
Intervention: Low-flow AS (defined as stroke volume index <22 ml/m²)
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: Increasing LV global load
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: LV global load
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: Ejection Fraction (EF)
Number of subjects: 1591
Study: 17502568

Group type: EXPERIMENTAL
Intervention: Primary stenting with self‐expanding nitinol stents
Number of subjects: 104
Study: 14692904

Group type: EXPERIMENTAL
Intervention: Intermediate intervention: Postal dissemination of the guideline supported by interactive, accredited workshops, and dedicated, structured protocol documents.
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Intensive intervention: Intermediate intervention plus a nurse specialist who supported and educated practices in the establishment of epilepsy review clinics.
Number of subjects: 1133

Group type: COMPARATOR
Intervention: Control: Postal dissemination of a nationally developed clinical guideline.
Number of subjects: 1133
Study: 11668354

Group type: EXPERIMENTAL
Intervention: Subgroup analysis reported in RCT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methodological aspects of SA reporting
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Reporting of whether SA preceded/followed analysis
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall reporting of methodological aspects by journals
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Current reporting of SA in RCT
Number of subjects: 32
Study: 9480993

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at doses of 5, 20, or 80 ppm
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control (0 ppm)
Number of subjects: 155
Study: 8092502

Group type: EXPERIMENTAL
Intervention: Arterial tonometry
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oscillometry
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Arterial tonometry (after correction for calibration error)
Number of subjects: 17
Study: 2963048

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31037994

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Famotidine 40 mg daily
Number of subjects: 80
Study: 30056389

Group type: EXPERIMENTAL
Intervention: Routine aspirin 75 mg from 11 until 36 weeks
Number of subjects: 546

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Screening test indicated aspirin
Number of subjects: 546
Study: 26830505

Group type: EXPERIMENTAL
Intervention: Breakfast consumption (non-skipper)
Number of subjects: 832

Group type: COMPARATOR
Intervention: Breakfast skippers
Number of subjects: 832
Study: 25661416

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 24044387

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel
Number of subjects: 140

Group type: COMPARATOR
Intervention: Proparacaine 0.5% eye drops
Number of subjects: 140
Study: 20050764

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg/night
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low-dose transdermal estradiol 25 microg/day
Number of subjects: 45
Study: 18218061

Group type: EXPERIMENTAL
Intervention: Telephone-based dietary counselling
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standardized, written nutritional information
Number of subjects: 43
Study: 16303296

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB) with AE
Number of subjects: 8

Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB) without AE
Number of subjects: 8

Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB) with AE using PSV
Number of subjects: 8

Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB) with AE using PAV
Number of subjects: 8
Study: 11960591

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms
Number of subjects: 0
Study: 10407218

Group type: EXPERIMENTAL
Intervention: Melatonin (5mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7555484

Group type: EXPERIMENTAL
Intervention: Policosanol (5 mg, twice a day for 12 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 2129189

Group type: EXPERIMENTAL
Intervention: Cefoxitin (2 g intravenous, single dose 30 minutes before the operation)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 78
Study: 7293522

Group type: EXPERIMENTAL
Intervention: Voltaren 100 mg suppositories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naprosyn 500 mg suppositories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naprosyn tablets
Number of subjects: 0
Study: 31535199

Group type: EXPERIMENTAL
Intervention: Home rectal irrigation (group A)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Healthy control group (group C)
Number of subjects: 122
Study: 28731600

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable (F&V) concentrate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 26593941

Group type: EXPERIMENTAL
Intervention: 250 mg of C. forskohlii extract, twice daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo, twice daily for 12 weeks
Number of subjects: 30
Study: 23352776

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 21352079

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day) plus Telmisartan (80 mg/day)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day) plus Irbesartan (300 mg/day)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day) plus Olmesartan (20 mg/day)
Number of subjects: 151
Study: 19181476

Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 0
Study: 17632075

Group type: EXPERIMENTAL
Intervention: Analytical rumination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiential rumination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0